# HOVON150AML (NCT03839771)

> A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03839771
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
- Interventions: AG-120; Placebo for AG-120; AG-221; Placebo for AG-221
- Enrollment: 968
- Primary outcome: Event-free survival (EFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 1
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=hovon150aml-nct03839771